FTSHI2 Antibody
Shipped with Ice Packs 
In Stock 
Product Specs
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Lead Time
Made-to-order (14-16 weeks)
Synonyms
FTSHI2 antibody; EMB2083 antibody; At3g16290 antibody; MYA6.12 antibody; T2O4.19Probable inactive ATP-dependent zinc metalloprotease FTSHI 2 antibody; chloroplastic antibody; AtFTSHI2 antibody; Protein EMBRYO DEFECTIVE 2083 antibody; Protein FTSH INACTIVE PROTEASE 2 antibody
Target Names
FTSHI2
Uniprot No.
Target Background
Function
This antibody targets FTSHI2, a protein essential for plastid development during embryogenesis. It may be involved in chaperone functions or play a structural role within the thylakoid FtsH complex.
Database Links
Protein Families
AAA ATPase family; Peptidase M41 family
Subcellular Location
Plastid, chloroplast membrane; Multi-pass membrane protein.
Q&A
The following FAQs address key research considerations for working with FTSHI2 Antibody in academic settings, synthesized from methodological frameworks in immunology literature and assay development principles. Data integration focuses on antibody validation, experimental design optimization, and conflict resolution in FSH-related studies.
Advanced Research Questions
How to resolve contradictions between FSH immunoassay results and functional data?
-
Scenario: High antibody binding but no phenotypic change
What computational tools enhance epitope characterization for FTSHI2?
| Tool | Application | Output Metric |
|---|---|---|
| PyMOL | Structural alignment vs. FSHα | Root-mean-square deviation (RMSD) |
| HADDOCK | Docking simulations with FSHR | Binding energy (ΔG) |
| BLASTp | Cross-species epitope conservation | Sequence identity % |
Methodological Conflict Analysis
7. Discrepancies in reported FSH blocking efficacy (in vitro vs. in vivo):
-
Key Variables:
-
Resolution Strategy:
-
Compare IC50 values across cell types (Table 1)
-
Use Fab fragments to isolate target effects
-
Table 1: FTSHI2 Inhibition Efficiency
| Cell Type | IC50 (nM) | Assay Type |
|---|---|---|
| RAW264.7 | 5.4 | Osteoclast TRAP |
| 3T3-L1 | 6.1 | Adipogenesis |
| Human granulosa | 8.2 | cAMP production |
Source: Adapted from in vitro validation studies
Validation & Reproducibility Framework
How to standardize inter-laboratory FTSHI2 validation?
-
Shared Reagents:
-
Blinded Analysis:
What metrics confirm antibody stability under varied storage conditions?
| Condition | Duration | Activity Retention | Assessment Method |
|---|---|---|---|
| 4°C (lyophilized) | 6 months | 98% ± 2% | SPR binding kinetics |
| -80°C (liquid) | 12 months | 95% ± 3% | Neutralization assay |
Quick Inquiry
Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
